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Abstract
Background: The aim of this study was to evaluate the clinical efficiency of transduodenal ampullectomy (TDA)
compared to conventional pancreatoduodenectomy (PD) in patients with early ampullary cancers.
Methods: We carried out a retrospective study by reviewing the medical records of 43 patients with early
ampullary cancer who underwent either TDA or PD from January 2001 to December 2014. TDA and PD were
performed on 22 patients and 21 patients, respectively. Clinical data, perioperative clinical outcomes and prognosis
were evaluated. The median follow-up was 75 (range, 38–143) months.
Results: The sensitivity of intraoperative frozen resection was 100 % (4/4) and 94.9 % (37/39) in patients with pTis
and pT1 tumors compared to final histologic diagnoses. The 5-year survival rate of patients with early ampullary
cancer was 77.3 % in TDA group and 75.9 % in PD group (P = 0.927). Patients with lymph node metastasis
presented a shorter 5-year survival rate (P = 0.014). TDA was associated with lower surgical morbidity (P = 0.033),
estimated blood loss (P = 0.002), medical cost (P = 0.028) compared to PD. No pancreatic fistula and surgical
mortality occurred in TDA group.
Conclusions: TDA could produce satisfactory clinical efficiency in patients fulfilled the following criteria
simultaneously: pTis or pT1 stage, tumor size≤ 2 cm, without lymph node metastasis. To achieve favorable
outcomes, intraoperative frozen section examinations should be reliable and resection margins should be negative.
Keywords: Transduodenal ampullectomy, Pancreatoduodenectomy, Lymph node metastasis, Early ampullary
cancer, Free resection margin
Background
Ampullary cancer is an exceptionally uncommon gastro-
intestinal tumor with an incidence of 0.4–0.5 per 100,000
per year, which accounts for about 5 % of all gastrointes-
tinal cancer diagnosed every year [1, 2]. It’s the second
most common cancer after pancreatic cancer in the peri-
ampullary region and accounts for about 6–20 % of peri-
ampullary tumors [3]. It has been reported that ampullary
cancer could be developed from adenomas by the
adenoma-carcinoma progress similar to the development
of colorectal cancer, which could be supported by the fact
that up to 50 % of ampullary villous tumors harbored local
adenocarcinoma at the time of diagnose and 80 % of
ampullary adenocarcinomas contain adenomatous tissue
[4, 5]. Therefore, there is no doubt that both benign and
malignant ampullary lesions should be resected if condi-
tions permit [2].
Pancreatoduodenectomy (PD), or Whipple procedure,
was once considered as the only choice for the manage-
ment of both benign and malignant tumors of the ampulla
and the radical procedure could achieve a 5-year survival
rate of 59.8 % for various stages and 83.7 % for early ampul-
lary cancers (pTis, pT1), respectively [6]. However, PD also
brings about relatively high surgical morbidity (25–50 %)
and quite worrisome surgical mortality (approximately 5 %)
despite the improvement of surgical techniques [7–9].
Transduodenal ampullectomy (TDA) has been proposed
for more than one century since 1899 and it has been
readmitted in the treatment of early ampullary tumors
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recently [10, 11]. TDA is a less invasive and simple tech-
nique, which could potentially provide equivalent clinical
outcomes for early ampullary tumors compared to radical
PD, while the indications for this local ampullectomy are
still controversial. Previous studies have demonstrated the
risk factors which would have an impact for the criteria of
performing TDA. Lymph node metastasis, lymphatic inva-
sion, resection margin and depth of invasion were critical
prognostic factors [6, 12]. Some other factors were also
reported to be associated with the prognosis of ampullary
tumors, including pancreas invasion, perineural invasion,
pathological subtype, grade of differentiation, tumor bud-
ding and intraoperative transfusion [6, 11, 13]. To achieve
satisfactory clinical outcomes of TDA, two criteria should
be taken into consideration: no lymph node metastasis and
negative resection margin [5, 6]. Based on previous studies,
we performed a retrospective study on whether TDA would
be of any benefit to selected patients with early ampullary
cancers compared to PD.
Methods
Patients
This study was approved by the ethics committee of
the Shanghai Jiao Tong University Affiliated Sixth
People’s Hospital and was performed in accordant
with the Declaration of Helsinki Principles. Informed
consent was obtained from each patient. Between
January 2001 and December 2014, medical records of
43 patients with early ampullary cancer admitted to
the Shanghai Jiao Tong University Affiliated Sixth
People’s Hospital were reviewed. Early ampullary
tumor was defined as tumor that confined to mucosa
and ampulla of Vater or sphincter of Oddi according
to American Joint Committee on Cancer (AJCC) 2010
staging [14]. The qualified patients received either TDA or
PD procedure and they didn’t receive radiotherapy or
chemotherapy. Clinicopathological characteristics were ob-
tained including demographics, clinical presentations and
postoperative outcomes. Postoperative mortality was de-
fined as in-hospital or 30-day death, as well as with the
morbidity recorded. Pancreatic fistula was defined and
graded according to the International Study Group reco-
mandations [15]. Follow-up information was obtained by
either telephone interviews or outpatient visits.
Surgery
All patients who met the following criteria were consid-
ered as suitable for TDA: 1) no lymph node metastasis
was detected by imaging examinations and intraopera-
tive frozen resection biopsy; 2) depth of invasion was
limited to Tis and T1; 3) lesions no more than 2 cm. Al-
though early ampullary cancer patients with systemic
morbidities, such as pulmonary, cardiac and vascular
disease, also received TDA, they weren’t included in this
study to avoid confounding factors. If patients didn’t
agree to receive this less invasive surgery, then PD pro-
cedure was performed. If patients didn’t fulfill the above
criteria, conventional PD procedure was performed pref-
erentially. Based on different surgical procedures, we
categorized these patients into TDA group (n = 22) and
PD group (n = 21).
Surgical technique of TDA has been described in previ-
ous literatures in detail [5, 16]. In short, after an upper mid-
line incision, Kocher maneuver was then performed to
mobilize the descending part of duodenum. Routine lymph
node resection was performed and then sent for frozen
pathological examination to confirm negative lymph node
metastasis, including supraduodenal as well as anterior and
posterior lymph nodes of the pancreatic head. After en
block tumor was removed, both the tumor tissue and resec-
tion margin were sent for frozen pathological examination.
If the results fulfilled the potential local resection criteria,
then TDA continued; otherwise, the operation was con-
verted to radical PD. Then, common bile duct and pancre-
atic duct were reconstructed by a reliable interrupted full-
thickness suture. To reduce surgical morbidity, T-tube was
placed in the common bile duct and its distant end reached
to duodenal lumen and a rubber stent was placed into the
pancreatic duct. The transverse suture was applied to close
the duodenum to avoid duodenal stenosis. The main surgi-
cal process was demonstrated in Fig. 1. The surgical tech-
nique of PD has been described before [17, 18]. The
pancreatic anastomosis was done in an end-to-end tele-
scoped fashion into the jejunum. Routine intraoperative
drains were performed.
Statistical analysis
Statistical analysis was performed by SPSS 19.0 software
(IBM SPSS Inc., Chicago, IL, USA). Survival was mea-
sured from the date of surgery and follow-ups were
finished on the December 31, 2014. Categorical variables
were compared using chi-square/Fisher’s exact test. Con-
tinuous variables were compared by t test. Survival rates
were estimated by the Kaplan-Meier method, and log-
rank test were used to analyze the difference. A P value
of less than 0.05 was considered statistically significant.
Results
Demographics and clinical features
The demographics, clinical manifestations of 43 study sub-
jects were summarized in Table 1. Of the 43 patients (24
male and 19 female) diagnosed as early tumor of the VA, 4
pTis tumors and 18 pT1 tumors were in TDA group and
PD group only consisted of 21 pT1 tumors. No statistical
difference was observed between TDA group and PD group
regarding sex, age, clinical presentation, tumor size, carbo-
hydrate antigen 19–9 (CA19-9), carcinoembryonic antigen
(CEA). The mean age of the patients undergoing TDA and
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PD was 66.4 (range, 38–87) years and 64.7 (range, 36–83)
years. The clinical presentations in patients undergoing
TDA or PD were as follows, respectively: abdominal pain,
13 (59.1 %) and 10 (47.6 %); jaundice, 4 (18.2 %) and 5
(23.8 %); fever 5 (22.7 %) and 7 (33.3 %); nausea/vomiting, 3
(13.6 %) and 2 (9.5 %); asymptomatic, 4 (18.2 %) and 3
(14.3 %). Of the 7 asymptomatic patients, 5 were diagnosed
by the computed tomography (CT) and 2 by magnetic res-
onance imaging (MRI). The mean tumor size in TDA
group and PD group was 1.2 cm (range, 0.4–2.0 cm) and
1.2 cm (range, 0.6–2.3 cm). The lymph node metastasis
was identified in 28.6 % (6/21) in the PD group and patients
with lymph node metastasis are not qualified for TDA.
Pathologic findings
The preoperative, intraoperative and final pathological
examination results were depicted in Table 2. The pre-
operative endoscopic biopsy and intraoperative frozen
resection have been routine clinical practice in the
compound management of ampullary cancer in our de-
partment. A true positive result was determined by the
final paraffin resections. When the final histologic diag-
noses after TDA or PD procedure were compared with
preoperative endoscopic biopsy, the sensitivity was
50 % (2/4) and 76.9 % (30/39) in patients with pTis and
pT1 tumor, respectively. When the final histologic diag-
noses after surgical treatment were compared with the
intraoperative frozen resection, the sensitivity was
100 % (4/4) and 94.9 % (37/39) in patients with pTis
and pT1 tumor, respectively. The false negative results
were mainly due to misdiagnoses of chronic mucous
inflammation and adenoma with various level of dys-
plasia. Notably, the negative margin (R0) resections
were all achieved among the 43 patients according to
the final pathology.
Perioperative outcomes
In PD group, 1 of the 21 patients (4.7 %) died of pancreatic
fistula and intractable sepsis 10 days after PD procedure.
The surgical morbidity of PD group was significantly higher
than that of TDA group (47.6 % vs. 18.2 %, P = 0.033). Pan-
creatic fistula, as a vital complication, only occurred in PD
Fig. 1 Main surgical technique of TDA. a Preoperative CT image showed the ampullary tumor protruded into duodenal lumen as a bulging. b
Intraoperative photograph showed that local resection of the tumor started from the site of the 11 o’clock position. c Intraoperative photograph
showed the circumferential resection of the tumor was about 5–10 mm from the edge of the tumor. d Intraoperative photograph showed the
reconstructed ampullary region. T ampullary tumor; D duodenum; Ph pancreatic head; Apb ampullo-pancreatobiliary common duct; CBD common
biliary duct; Pd pancreatic duct
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group with a quite high incidence rate of 19.0 %. Subse-
quently, the lengths of postoperative stay were shorter in
TDA group compared to PD group (14.5 ± 4.8 days vs.
19.0 ± 7.9 days, P = 0.029). Similarly, patients undergoing
TDA could spend less medical cost than those undergoing
PD (7974.8 ± 4523.3 US dollar vs. 10813.5 ± 3541.8 US dol-
lar, P = 0.028). The recurrence rate in the TDA group
tended to be higher compared with the PD group, but the
statistical difference was not reached (31.8 % vs. 23.8 %, P
= 0.588). The operation time in TDA group was signifi-
cantly shorter than that in PD group (175 min vs. 315 min,
P < 0.001). Estimated blood loss during surgery was lower
in the TDA group than PD group (135 ml vs. 320 ml, P =
0.002) and intraoperative transfusion was performed in 4
patients in PD group, while no one in TDA group received
transfusion (Table 3).
Prognosis after surgical treatments
The median follow-up period was 75 (range, 38–143)
months. The 5-year survival rate of the early ampullary
in TDA group and PD group was 77.3 % (median sur-
vival time, 75 months) and 75.9 % (median survival time,
78 months) separately, which wasn’t statistically different
(P = 0.927) (Fig. 2a). Furthermore, the 5-year survival
rate of the whole 43 patients was 76.7 %. Regarding to
surgical procedures, in TDA group, patients with pTis
and pT1 showed 5-year survival rate of 100 % and
72.2 %, yet the difference didn’t reach statistical signifi-
cance (P = 0.928). Patients in PD group were all at pT1
stage. In order to exclude the impact of depth of inva-
sion and lymph node metastasis, 4 pTis patients in TDA
group and 6 patients with LN metastasis in PD group
were removed and the 5-year survival rate of the pa-
tients with pT1 undergoing TDA or PD were still not
significantly different (P = 0.545).
Lymph node (LN) metastasis was a critical predictive
factor for the prognosis of ampullary cancer, so we further
investigate the overall survival and LN metastasis. Of the
21 patients receiving the PD procedure, 6 (28.6 %) patients
had lymph node metastasis based on hematoxylin-eosin
staining and histological examinations. The 5-year survival
rate of patients in the PD group with LN metastasis was
significantly lower than that in the patients without LN
metastasis (P = 0.014) (Fig. 2b).
Discussion
The surgical treatments for ampullary cancer mainly in-
clude PD and TDA. PD is the standard surgical strategy
and TDA only accounts for about 4–6 % of cases of
resected ampullary tumors [1, 19]. Endoscopic ampullect-
omy is another choice for ampullary lesions, but it is only
suitable for low-grade and high-grade dysplasia, minor pa-
pilla adenoma [8, 20, 21]. For malignant ampullary tumors,
endoscopic ampullectomy is not recommended due to the
difficulty in the exact diagnose of early ampullary tumors,
potential lymph node metastasis and significant complica-
tions [22]. TDA is a less invasive procedure compared to
PD and it is likely to provide similar clinical outcomes for
selected early ampullary cancer patients [23, 24]. However,
the indications and clinical outcomes of TDA procedure
still require further investigation. In this study, TDA group
have similar 5-year survival rate and recurrence rate, but
lower surgical morbidity, estimated blood loss, intraopera-
tive transfusion and operation time compared with PD
Table 1 Demographics, clinical presentations, and CAV
characteristics
TDA (n = 22) PD (n = 21) P value
Sex 0.545
Male 13 (59.1 %) 11 (52.4 %)
Female 9 (40.9 %) 10 (47.6 %)
Age (years) 0.722
Median, range 68.0 (38–87) 67.0(36–83)
Symptom
Abdominal pain 13 (59.1 %) 10 (47.6 %) 0.451
Jaundice 4 (18.2 %) 5 (23.8 %) 0.937
Fever 5 (22.7 %) 7 (33.3 %) 0.538
Nausea/vomiting 3 (13.6 %) 2 (9.5 %) 1.000
Asymptomatic 4 (18.2 %) 3 (14.3 %) 1.000
Tumor Size (cm) 0.725
Mean, range 1.2 (0.4–2.0) 1.2 (0.6–2.3)
CA19-9 (U/ml) 3.20 ± 5.21 3.16 ± 2.16 0.957
CEA (ng/ml) 9.39 ± 5.21 12.07 ± 6.07 0.154
Depth of invasion 0.108
pTis 4 (18.2 %) 0 (0 %)
pT1 18 (81.8 %) 21 (100 %)
Lymph node metastasis 0.009
Positive 0 (0 %) 6 (28.6 %)
Negative 22 (100 %) 15 (71.4 %)
Table 2 Pathology on endoscopic biopsy, intraoperative frozen section, and final pathology
Final
pathology
Endoscopic biopsy Intraoperative frozen resection
Inflammation Adenoma Carcinoma Inflammation Adenoma Carcinoma
pTis (n = 4) 1 1 2 0 0 4
pT1 (n = 39) 2 7 30 0 2 37
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group, so the clinical value of TDA should be reconsidered.
Although T stage and LN metastasis were independent
prognostic factors, due to the small simple of patients with
pTis and LN metastasis, no significant difference was found
in the two groups. Specifically, when 5-year survival rate of
pT1 patients without LN metastasis in TDA group and PD
group were compared, there was still no significant differ-
ence, thus further implying that the equivalent clinical effi-
ciency of TDA procedure in this part of patients.
Lymph node metastasis was a major factor for postopera-
tive recurrence and overall survival [24, 25]. In our series,
the 5-year survival rate in early ampullary tumors with and
without lymph node metastasis was approximately 50 %
and 80 %, respectively. In T1 tumors, lymph node
metastasis is reported to decrease 5-year survival rate from
about 75 to 30 % [25, 26]. Besides, the 3-year recurrence
rate was significantly higher in patients with lymph node
metastasis compared to those without (38.2 % vs. 58.78 %)
[25]. In order to achieve operative curability in TDA pro-
cedure, lymph node metastasis shouldn’t appear in the se-
lected cases [6]. Negative lymph node metastasis is essential
for curative resection for ampullary cancer. Since pTis
tumor is only confined to the mucosa, so there is no poten-
tial lymph node metastasis and this phenomenon has been
confirmed by many studies. [2, 11]. In this regard, pTis
tumor is appropriate indication for local ampullectomy.
However, pT1 tumor has invaded to Sphincter of Oddi or
ampulla of Vater, so lymph node metastasis usually occurred
in 9–45.5 % of T1 tumors [11]. Masato Kayahara et al. re-
ported that the most important lymph node was posterior
pancreaticoduodenal lymph nodes and lymph nodes around
superior mesenteric artery, which occurred in 39 % and
17 % of 36 ampullary cancer patients in 1997, which could
be regarded as sentimental lymph nodes [26]. Afterwards,
surgeons became to pay special attention on the anterior
and posterior pancreatic lymph nodes and supraduodenal
lymph nodes [5, 27]. In this study, we also perform supra-
duodenal as well as anterior and posterior lymph nodes of
the pancreatic head and resulted in a comparable high clin-
ical outcome [13]. Therefore, it’s of utmost importance to
identify lymph node status before performing TDA.
Preoperative endoscopic biopsy is also routinely per-
formed with a diagnostic accuracy of 69–81 % [2]. Biop-
sies should be taken in 9 to 1 o’clock quadrant to avoid
inducing pancreatitis [8]. If the endoscopic biopsy showed
benign lesions, then TDA could be considered. Because
false-negative rate could be 10–38 %, so the possibility of
malignance couldn’t be excluded [2]. When the results
showed malignant tumors, more parameters, including
tumor size, depth of invasion and lymph node metastasis
Fig. 2 Kaplan-Meier plot. a Survival curve between TDA group and PD group, survive rate was calculated by the Kaplan-Meier method, significant
difference wasn’t found between the two groups (P = 0.927). b Overall survival rate in PD group according to the lymph node status, patients
without LN metastasis (N-)had better prognosis than these with LN metastasis (N+) (P = 0.014)
Table 3 Postoperative outcomes after TDA or PD




0 (0 %) 1 (4.8 %) 0.488
Surgical
morbidity,%
3 (13.6 %) 9 (42.8 %) 0.033
Pancreatic fistula 0 (0 %) 4 (19.0 %) 0.048
Wound infection 2 (9.1 %) 3 (14.3 %) 0.664
Bleeding 1 (4.5 %) 5 (23.8 %) 0.082
Lengths of stay,
days (mean, SD)
14.5 ± 4.8 19.0 ± 7.9 0.029
Medical cost, US
dollar
7974.8 ± 4523.3 10813.5 ± 3541.8 0.028




135 (60–370) 320 (120–1800) 0.002
Intraoperative
transfusion
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should be considered if TDA was about to be performed.
When the size of tumor was no more than 2 cm, the
depth of invasion was pTis or pT1 and there was no sign
of lymph node metastasis, TDA still could be considered
[5]. Compared to the limited accuracy of endoscopic
biopsy, the intraoperative biopsy could differentiate benign
and malignant tumors with a sensitivity of 97 % and speci-
ficity of 100 % [28]. In addition, frozen section examin-
ation during ampullectomy helped obtain free resection
margin and confirm the lymph node status [5]. In this
study, the sensitivity of frozen resection biopsy was 100 %
and 94.9 % for pTis and pT1 tumors, which could guaran-
tee reasonable managements.
Although tumor size was not related to the presence or
absence of malignancy and proximal ductal invasion, lymph
node metastasis tended to occur more frequently with the
size of tumor increasing [6, 10, 29]. Therefore, only when
the size of tumor was less than 2 cm, TDA was performed.
Since the small sample size of the patients with postopera-
tive occurrence, we could hardly draw meaningful conclu-
sions on the relationship between tumor size and
recurrence, so large-scale clinical experiment should be
designed to explore this issue. However, previous study
may cast light on the problem. Yoo-Seok Yoon et al. has
demonstrated that tumor size less than 1.0 cm, 1.1–1.5 cm,
1.6–2.0 cm showed lymph node metastasis rates of 11.6,
25.8, and 43.2 % [6]. In addition, lymph node metastasis
was an independent risk factor for prognosis, therefore, we
speculate that the smaller tumor size may be associated
with lower recurrence rate [6, 25]. In terms of R0 resection,
all of the cases in our series achieved the complete resec-
tion which contributed to improved 5-year survival, and
the predictive value wasn’t analyzed. However, other studies
have confirmed the prominent significance of R0 resection.
Beger et al. reported that patients with R0 resection had sig-
nificant superior survival comparing to these with R1 and
R2 resection and R0 resection proved to be one critical
prognostic factor [27]. It’s mandatory to ensure R0 resec-
tion for achieving long-term survival and we recommended
that the resection should be 5–10 mm from the edge of the
tumor if possible.
As to adjuvant chemoradiotherapy, on the one hand,
adjuvant chemoradiotherapy couldn’t significantly pro-
long overall survival and reduce recurrence rate, so
routine use of adjuvant chemoradiotherapy is not war-
ranted [30, 31]. On the other hand, the patients in this
study were early ampulllary tumors, while chemoradio-
therapy might only benefit some patients with ampul-
lary tumors with more invasive features [32]. Therefore,
adjuvant chemoradiotherapy was not administered on
this subset of patients. Additionally, local recurrence
was not significantly different in TDA group and PD
group. This result could be accounted by the fact that
adequate free resection margin and negative lymph
node metastasis was important for lower local recur-
rence [5, 25].
There are several limitations in this study. Since the
technique of TDA is not quite popular and indications for
this operation is not quite very obvious, study sample size
is small and this study has to take the 15 years’ experience
into consideration to produce significant statistical power.
However, since the operations were performed in a single
center and the same team, the surgical technique was
quite stable, thus minimizing the confounder confounding
factors. With the development of surgical technique and
clinical study, this operation may be more popular and
more cases will be available for further study. On the
other hand, because it is a respective study, there exists se-
lection bias and information bias, thus leading to less
strong evidence. Therefore, there is an urgent need for
prospective study by collaborating among multiple centers
for exploring proper indications and treatment regimens.
In general, the perioperative clinical outcomes in TDA
group were more favorable than these in PD group. Firstly,
there was no surgical mortality in TDA group but 1 patient
died of pancreatic fistula and intractable sepsis in PD group,
which was quite troublesome. Although the surgical mor-
tality of PD procedure has decreased to 5 % in high-volume
hospitals, the surgical mortality does exist and how to avoid
the mortality is very crucial [33]. Secondly, the surgical
morbidity length of stay in TDA group was significantly
lower compared to PD group and what’s more, pancreatic
fistula didn’t occur in TDA group but occurred in 19 % of
patients in PD group. Pancreatic fistula was a serious surgi-
cal morbidity and occurred in 5–30 % of patients, which
could result in intra-abdominal abscess, sepsis, and even
death [34]. Therefore, pancreatic fistula was a great chal-
lenge that waited to be solved or circumvented by hepato-
pancreaticobiliary surgeon. Thirdly, blood loss was much
less and no intraoperative transfusion was needed in TDA
group; in contrast, 19.0 % of patients received transfusion
in PD group. Since intraoperative transfusion was associ-
ated with recurrence and shorter survival, the unnecessary
blood transfusion should be avoided [35, 36]. Lastly but not
least, medical cost in TDA group was lower than that in
PD group due to lower and milder surgical morbidity and
shorter length of stay, which will also be beneficial to
patients.
Conclusion
The TDA procedure is suitable for ampullary cancer pa-
tients fulfilled the following criteria simultaneously: pTis
or pT1 stage, tumor size ≤ 2 cm, without lymph node me-
tastasis. TDA procedure is feasible for selected patients
with similar 5-year survival rate and lower surgical com-
plications. Notably, TDA procedure should be based on
reliable endoscopic biopsy, intraoperative frozen section
examinations, and negative resection margins. Due to the
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number of patients was small in this study, more clinical
studies should be carried out to validate the safety and
efficiency of the TDA in qualified patients.
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